Imatinib-Mesylate Induced Interstitial Pneumonitis in Two CML Patients / 결핵및호흡기질환
Tuberculosis and Respiratory Diseases
;
: 210-215, 2011.
Artículo
en Inglés
| WPRIM
| ID: wpr-182755
ABSTRACT
Imatinib mesylate, a selective inhibitor of BCR-ABL kinase activity, has demonstrated significant clinical efficacy in the treatment of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). It has become the standard of treatment for these diseases. Although the toxicity profile of imatinib is superior to that of interferon or other cytotoxic agents, some adverse events including edema, gastrointestinal toxicities and hematologic toxicities are commonly observed in the patients treated by imatinib. We present two cases of imatinib induced interstitial pneumonitis during the treatment of a chronic phase of CML.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Fosfotransferasas
/
Piperazinas
/
Pirimidinas
/
Benzamidas
/
Leucemia Mielógena Crónica BCR-ABL Positiva
/
Interferones
/
Enfermedades Pulmonares Intersticiales
/
Mesilatos
/
Citotoxinas
/
Tumores del Estroma Gastrointestinal
Límite:
Humanos
Idioma:
Inglés
Revista:
Tuberculosis and Respiratory Diseases
Año:
2011
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS